Navigation Links
Fear of insurance rejection deters potentially life saving genetic tests for bowel cancer
Date:9/5/2009

An Australian study of families with genetic risk of bowel cancer has found that 50 percent of participants declined genetic testing when informed of insurance implications.

"This indicates that people have a significant fear of insurance discrimination which impacts their decision to have potentially life saving genetic testing," says co-lead author Dr Louise Keogh, of the University of Melbourne's Key Centre for Women's Health in Society.

The population-based study was led by researchers from the University of Melbourne and the Cancer Council Victoria, and published in the prestigious Medical Journal of Australia today.

Researchers identified 106 people from 25 families in which there were genetic mutations that increase the risk of bowel cancer. All were offered the chance to learn their own individual genetic information at a Familial Cancer Clinic.

"When we told participants about the life insurance implications of genetic testing, the number declining genetic testing more than doubled from 20 per cent to 50 per cent," Dr Keogh said.

"In Australia, while genetic information has no implications for health insurance, it can affect life, trauma, disability and sickness and accident insurance policies, "says co-lead author Christine van Vliet, School of Medical Sciences, University of New South Wales.

"However this is not the case in all countries. Since we know all people have some genes which predispose to disease, it is important that the Australian life insurance industry does not deter people from learning about their genetic risks," she says.

Bowel cancer is the second most common cancer for men and women in Australia. One in every 3,000 Australians carry a genetic mutation that places them at high risk of bowel cancer.

"For those at high genetic risk, screening for and removal of polyps reduces the risk of bowel cancer by more than 50 percent," says Associate Professor Mark Jenkins of the University of Melbourne's School of Population Health and senior author on the paper.

"Insurance-related apprehension about genetic testing could have troubling public health consequences. Screening people at high genetic risk of bowel cancer is a highly cost effective way to reduce deaths due to bowel cancer," he says.

Dr Louise Keogh says that now that we know insurance policies are adversely affecting health decision-making, it is time to act.

"We call on the Federal Government and the Australian insurance industry to look at what other countries have done and reconsider the use of genetic information where genetic testing has the potential to reduce morbidity and mortality," she says.

People with a strong family history of bowel cancer and concerned about the possibility of having inherited a high risk can obtain a referral from a GP to visit a Family Cancer Clinic.


'/>"/>

Contact: Rebecca Scott
rebeccas@unimelb.edu.au
61-383-440-181
University of Melbourne
Source:Eurekalert

Related biology news :

1. CIC Teams With Industry Leader iPipeline to Provide Electronic Signature Platform to the Nations Top Insurance Carriers
2. CIC to Host Webinar Featuring Independent Research Firm: Enabling Straight Through Processing - Why the Insurance Industry Needs Electronic Signature Technology
3. No insurance? No colonoscopy
4. Northwestern Memorial trial may wean kidney transplant patients off antirejection drugs
5. Childrens Hospital researchers identify genetic mutation that may predict organ rejection
6. Embryonic stem cells might help reduce transplantation rejection
7. Female plant communicates rejection or acceptance of male
8. Unexpected finding opens up new way to stop autoimmune diseases and transplant rejection
9. Researchers explore new driver of transplant rejection: Platelets
10. Gene mutation increases drug toxicity, rejection risk in pediatric kidney transplants
11. Researchers find genetic link between physical pain and social rejection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
(Date:3/24/2017)... , March 24, 2017 The Controller General ... Controller Mr. Abdulla Algeen have received the prestigious international IAIR ... Continue Reading ... ... picture) and Deputy Controller Abdulla Algeen (small picture on the right) have ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... DIEGO , March 27, 2017  Trovagene, Inc. ... that its Chief Executive Officer, Bill Welch , ... April 4, 2017 at 9:00 AM EDT at the ... .  Bill Welch, and Chief Scientific Officer, Mark ... with investors during the conference.   The presentation ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Human ... report to their offering. ... This report analyzes the Global market for Human Embryonic ... are provided for the period 2014 through 2022. Market data and ... The report profiles 25 companies including many key and niche players ...
(Date:3/23/2017)... ... 2017 , ... AxioMed president, Jake Lubinski, describes the AxioMed ... deformed, which is identical to how the human discs work to distribute force. ... to its natural state along a hysteresis curve, exactly like a healthy human ...
(Date:3/23/2017)... 2017  GlobeImmune, Inc. today announced it has entered ... 12,835,490 shares of its common stock to NantCell, Inc., ... with the sale of its common stock, NantCell has ... to GlobeImmune 200,000 shares, an estimated $2.0 million in ... are pleased to enter into this strategic agreement with ...
Breaking Biology Technology: